Dolby Laboratories, Inc.
DLB · NYSE
9/26/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -9.32 | 0.75 | 4.35 | -0.88 |
| FCF Yield | 6.20% | 4.07% | 4.44% | 3.98% |
| EV / EBITDA | 16.58 | 16.96 | 19.75 | 18.62 |
| Quality | ||||
| ROIC | 8.00% | 8.22% | 8.20% | 7.61% |
| Gross Margin | 88.13% | 88.97% | 88.26% | 88.73% |
| Cash Conversion Ratio | 1.84 | 1.24 | 1.82 | 1.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.25% | 0.53% | 0.48% | 2.57% |
| Free Cash Flow Growth | 44.75% | -11.73% | 29.96% | -34.12% |
| Safety | ||||
| Net Debt / EBITDA | -1.75 | -1.33 | -2.22 | -1.81 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 5.26 | 4.17 | 4.28 | 6.00 |
| Cash Conversion Cycle | 167.18 | 189.46 | 159.96 | 146.39 |